Analyst: J&J could reap $1 billion from patent extension for Topamax (The Star-Ledger)

Analyst: J&J could reap $1 billion from patent extension for Topamax (The Star-Ledger)
Johnson & Johnson could reap an extra $1 billion in sales from its migraine and epilepsy treatment Topamax, now that federal regulators have extended its patent by six months, an analyst said today.